Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:GLSI NASDAQ:PALI NYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.90+2.3%$5.02$4.00▼$7.54$335.61M1.351.20 million shs852,657 shsGLSIGreenwich LifeSciences$22.86-3.2%$25.07$7.78▼$34.10$316.73M1.39295,735 shs74,619 shsPALIPalisade Bio$1.80-9.5%$1.98$0.53▼$2.86$301.36M1.524.34 million shs3.02 million shsXTNTXtant Medical$0.52-8.8%$0.55$0.44▼$0.95$72.84M-0.11157,137 shs285,371 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-3.99%+5.68%+19.96%+12.48%+9.53%GLSIGreenwich LifeSciences+2.43%0.00%+4.93%-18.55%+154.25%PALIPalisade Bio-0.50%-0.50%+4.19%+21.34%+161.84%XTNTXtant Medical-1.23%+8.92%+25.00%-3.60%+9.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.90+2.3%$5.02$4.00▼$7.54$335.61M1.351.20 million shs852,657 shsGLSIGreenwich LifeSciences$22.86-3.2%$25.07$7.78▼$34.10$316.73M1.39295,735 shs74,619 shsPALIPalisade Bio$1.80-9.5%$1.98$0.53▼$2.86$301.36M1.524.34 million shs3.02 million shsXTNTXtant Medical$0.52-8.8%$0.55$0.44▼$0.95$72.84M-0.11157,137 shs285,371 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-3.99%+5.68%+19.96%+12.48%+9.53%GLSIGreenwich LifeSciences+2.43%0.00%+4.93%-18.55%+154.25%PALIPalisade Bio-0.50%-0.50%+4.19%+21.34%+161.84%XTNTXtant Medical-1.23%+8.92%+25.00%-3.60%+9.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.60Moderate Buy$19.00222.03% UpsideGLSIGreenwich LifeSciences 2.33Hold$47.50107.79% UpsidePALIPalisade Bio 2.88Moderate Buy$10.20466.67% UpsideXTNTXtant Medical 3.00Buy$1.0092.31% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, PALI, ABEO, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/8/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.003/31/2026XTNTXtant Medical BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1.50 ➝ $1.003/26/2026PALIPalisade Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.003/19/2026ABEOAbeona Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.003/18/2026XTNTXtant Medical Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/17/2026ABEOAbeona Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.003/10/2026ABEOAbeona Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.003/9/2026ABEOAbeona Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform2/25/2026PALIPalisade Bio Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$5.82M57.66N/AN/A$2.94 per share2.01GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/APALIPalisade Bio$250K1,205.42N/AN/A$0.87 per share2.07XTNTXtant Medical$133.93M0.54$0.07 per share7.92$0.36 per share1.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics$71.18M$1.035.7310.73N/AN/A-60.65%-40.78%5/13/2026 (Estimated)GLSIGreenwich LifeSciences-$15.79M-$1.46N/AN/AN/AN/A-1,042.84%-565.43%5/19/2026 (Estimated)PALIPalisade Bio-$16.78M-$2.12N/AN/AN/AN/A-47.76%-42.98%5/11/2026 (Estimated)XTNTXtant Medical$4.97M-$0.1317.34N/AN/A3.71%10.27%4.98%5/12/2026 (Estimated)Latest XTNT, PALI, ABEO, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026N/AGLSIGreenwich LifeSciences-$0.33N/AN/AN/AN/AN/A5/13/2026Q1 2026ABEOAbeona Therapeutics-$0.34N/AN/AN/A$4.57 millionN/A5/12/2026Q1 2026XTNTXtant Medical-$0.0150N/AN/AN/A$20.16 millionN/A5/11/2026Q1 2026PALIPalisade Bio-$0.04N/AN/AN/AN/AN/A3/31/2026Q4 2025XTNTXtant Medical-$0.0049$0.0263+$0.0312N/A$30.75 million$32.36 million3/17/2026Q4 2025ABEOAbeona Therapeutics-$0.35-$0.34+$0.01-$0.34$5.65 million$3.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.056.936.74GLSIGreenwich LifeSciencesN/A2.352.35PALIPalisade BioN/A28.9528.95XTNTXtant Medical0.222.651.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%GLSIGreenwich LifeSciences4.16%PALIPalisade Bio11.79%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%GLSIGreenwich LifeSciences51.47%PALIPalisade Bio0.05%XTNTXtant Medical10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9056.88 million52.96 millionOptionableGLSIGreenwich LifeSciences313.86 million6.72 millionNot OptionablePALIPalisade Bio10167.42 million167.34 millionNot OptionableXTNTXtant Medical120140.07 million125.50 millionNot OptionableXTNT, PALI, ABEO, and GLSI HeadlinesRecent News About These CompaniesXtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026May 7 at 8:00 AM | prnewswire.comXtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ ShapedMay 6 at 8:00 AM | prnewswire.comXtant Medical (XTNT) Expected to Announce Earnings on TuesdayMay 5 at 1:06 PM | marketbeat.comXtant Medical Holdings (XTNT) price target increased by 12.12% to 1.26April 28, 2026 | msn.comXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 67.8% in AprilApril 25, 2026 | marketbeat.comXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Growth in Short InterestApril 13, 2026 | marketbeat.comXtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows ProductApril 13, 2026 | prnewswire.comXtant Medical Holdings (XTNT) price target decreased by 18.52% to 1.12April 10, 2026 | msn.comXtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" MemorialApril 9, 2026 | prnewswire.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2025 Earnings Call TranscriptApril 1, 2026 | insidermonkey.comXtant outlines $95M-$99M 2026 revenue outlook as Companion Spine divestiture and Q-code license revenue roll offMarch 31, 2026 | msn.comXtant Medical shares drop nearly 5% as weak 2026 outlook overshadows Q4 beatMarch 31, 2026 | msn.comXtant Medical Holdings Inc (XTNT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...March 31, 2026 | finance.yahoo.comXtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call TranscriptMarch 31, 2026 | seekingalpha.comXtant Medical Reports Fourth Quarter and Full-Year 2025 Financial ResultsMarch 31, 2026 | prnewswire.comXtant Medical Holdings (XTNT) price target decreased by 10.00% to 1.38March 28, 2026 | msn.comXtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026March 25, 2026 | prnewswire.comXtant Medical completes transactions with Companion SpineMarch 4, 2026 | massdevice.comXtant Medical Finalizes Companion Spine TransactionsMarch 2, 2026 | prnewswire.comXtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal ConferenceFebruary 25, 2026 | prnewswire.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Down 5.29%January 3, 2026 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTNT, PALI, ABEO, and GLSI Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.90 +0.13 (+2.25%) Closing price 04:00 PM EasternExtended Trading$5.89 -0.01 (-0.10%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Greenwich LifeSciences NASDAQ:GLSI$22.86 -0.76 (-3.22%) Closing price 04:00 PM EasternExtended Trading$22.90 +0.05 (+0.20%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Palisade Bio NASDAQ:PALI$1.80 -0.19 (-9.55%) Closing price 04:00 PM EasternExtended Trading$1.82 +0.02 (+1.11%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Xtant Medical NYSEAMERICAN:XTNT$0.52 -0.05 (-8.77%) As of 04:10 PM EasternXtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
